[go: up one dir, main page]

FI971406A0 - TIE-2-ligandeja ja menetelmiä niiden valmistamiseksi ja käyttämiseksi - Google Patents

TIE-2-ligandeja ja menetelmiä niiden valmistamiseksi ja käyttämiseksi

Info

Publication number
FI971406A0
FI971406A0 FI971406A FI971406A FI971406A0 FI 971406 A0 FI971406 A0 FI 971406A0 FI 971406 A FI971406 A FI 971406A FI 971406 A FI971406 A FI 971406A FI 971406 A0 FI971406 A0 FI 971406A0
Authority
FI
Finland
Prior art keywords
tie
provides
human
growth
ligand
Prior art date
Application number
FI971406A
Other languages
English (en)
Swedish (sv)
Other versions
FI971406A7 (fi
FI120313B (fi
Inventor
Samuel Davis
Joanne Bruno
Mitchell Goldfarb
Thomas H Aldrich
Peter C Maisonpierre
Czaslaw Radziejewski
Pamela F Jones
George D Yancopoulos
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/319,932 external-priority patent/US5643755A/en
Priority claimed from US08/348,492 external-priority patent/US5879672A/en
Priority claimed from US08/373,579 external-priority patent/US5650490A/en
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of FI971406A0 publication Critical patent/FI971406A0/fi
Publication of FI971406A7 publication Critical patent/FI971406A7/fi
Application granted granted Critical
Publication of FI120313B publication Critical patent/FI120313B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
FI971406A 1994-10-07 1997-04-04 TIE-2-ligandit, niiden valmistusmenetelmät ja käytöt FI120313B (fi)

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US31993294 1994-10-07
US08/319,932 US5643755A (en) 1994-10-07 1994-10-07 Nucleic acid encoding tie-2 ligand
US33026194 1994-10-27
US08/330,261 US5521073A (en) 1994-10-07 1994-10-27 TIE-2 ligand, and method of making
US34849294 1994-12-02
US08/348,492 US5879672A (en) 1994-10-07 1994-12-02 Tie-2 ligand 1
US35350394A 1994-12-09 1994-12-09
US35350394 1994-12-09
US37357995 1995-01-17
US08/373,579 US5650490A (en) 1994-10-07 1995-01-17 Tie-2 ligand 2
US41859595 1995-04-06
US08/418,595 US5814464A (en) 1994-10-07 1995-04-06 Nucleic acids encoding TIE-2 ligand-2
PCT/US1995/012935 WO1996011269A2 (en) 1994-10-07 1995-10-06 Tie-2 ligands, methods of making and uses thereof
US9512935 1995-10-06

Publications (3)

Publication Number Publication Date
FI971406A0 true FI971406A0 (fi) 1997-04-04
FI971406A7 FI971406A7 (fi) 1997-06-04
FI120313B FI120313B (fi) 2009-09-15

Family

ID=27559710

Family Applications (1)

Application Number Title Priority Date Filing Date
FI971406A FI120313B (fi) 1994-10-07 1997-04-04 TIE-2-ligandit, niiden valmistusmenetelmät ja käytöt

Country Status (22)

Country Link
US (4) US5814464A (fi)
EP (1) EP0784683B1 (fi)
JP (1) JP4054375B2 (fi)
CN (1) CN1230536C (fi)
AT (1) ATE199259T1 (fi)
AU (1) AU711111B2 (fi)
CA (1) CA2202028C (fi)
CZ (1) CZ292453B6 (fi)
DE (1) DE69520149T2 (fi)
DK (1) DK0784683T3 (fi)
ES (1) ES2154354T3 (fi)
FI (1) FI120313B (fi)
GR (1) GR3035717T3 (fi)
HU (1) HU221422B1 (fi)
IL (4) IL115517A (fi)
MX (1) MX9702530A (fi)
NO (1) NO322643B1 (fi)
NZ (1) NZ296638A (fi)
PL (1) PL184642B1 (fi)
PT (1) PT784683E (fi)
WO (1) WO1996011269A2 (fi)
ZA (1) ZA958444B (fi)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681714A (en) * 1992-07-30 1997-10-28 Mount Sinai Hospital Corporation Nucleic acid encoding tek receptor tyrosine kinase
US6130071A (en) * 1997-02-05 2000-10-10 Helsinki University Licensing, Ltd. Vascular endothelial growth factor C (VEGF-C) ΔCys156 protein and gene, and uses thereof
US6221839B1 (en) 1994-11-14 2001-04-24 Helsinki University Licensing Ltd. Oy FIt4 ligand and methods of use
US6245530B1 (en) 1995-08-01 2001-06-12 Ludwig Institute For Cancer Research Receptor ligand
US6645933B1 (en) 1995-08-01 2003-11-11 Helsinki University Licensing Ltd. Oy Receptor ligand VEGF-C
US6403088B1 (en) 1995-08-01 2002-06-11 Helsinki University Licensing, Ltd. Antibodies reactive with VEGF-C, a ligand for the Flt4 receptor tyrosine kinase (VEGFR-3)
US6818220B1 (en) 1994-11-14 2004-11-16 Licentia Ltd. Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof
AU755337B2 (en) * 1995-04-06 2002-12-12 Regeneron Pharmaceuticals, Inc. New uses of tie-2 ligands
CA2216963C (en) * 1995-04-06 2010-06-22 Regeneron Pharmaceuticals, Inc. Tie-2 ligands, methods of making and uses thereof
US6361946B1 (en) 1997-02-05 2002-03-26 Licentia Ltd Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US7727761B2 (en) 1995-08-01 2010-06-01 Vegenics Limited Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
DE69638142D1 (de) 1995-09-29 2010-04-15 Univ Siena Regulierte Gene und ihre Verwendungen
US7063965B2 (en) * 1996-04-05 2006-06-20 Regeneron Pharmaceuticals, Inc. Nucleic acid encoding TIE-2 ligand
DE19623850A1 (de) * 1996-06-14 1997-12-18 Wacker Chemie Gmbh Homogenisierung von Dispersionen
US5851797A (en) * 1996-06-19 1998-12-22 Regeneron Pharmaceuticals, Inc. Tie ligand-3, methods of making and uses thereof
NZ333374A (en) 1996-06-19 2000-06-23 Regeneron Pharma TIE-2 receptor ligands (TIE ligand-3 and TIE ligand-4) and their uses as antagonists of TIE and for blocking blood vessel growth or preventing tumour growth
US6846914B2 (en) 1996-06-19 2005-01-25 Regeneron Pharmaceuticals, Inc. Tie-2 ligand-3
US6265564B1 (en) 1996-08-02 2001-07-24 Regeneron Pharmaceuticals, Inc. Expressed ligand-vascular intercellular signalling molecule
CA2263890C (en) 1996-08-23 2013-05-14 Ludwig Institute For Cancer Research Recombinant vascular endothelial cell growth factor d (vegf-d)
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
US5972338A (en) 1997-09-19 1999-10-26 Genentech, Inc. Tie ligands homologues
US6350450B1 (en) 1997-09-19 2002-02-26 Genentech, Inc. TIE ligand homologue antibody
US6057435A (en) * 1997-09-19 2000-05-02 Genentech, Inc. Tie ligand homologues
US6348350B1 (en) 1997-09-19 2002-02-19 Genentech, Inc. Ligand homologues
US6030831A (en) * 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
EP1038006A1 (en) * 1997-12-19 2000-09-27 Regeneron Pharmaceuticals, Inc. Receptor tyrosine kinase, ar-1, is a regulator of angiogenesis
AU1931599A (en) * 1997-12-19 1999-07-12 Zymogenetics Inc. Angiopoietin homolog, dna encoding it, and method of making it
WO1999040193A1 (en) * 1998-02-04 1999-08-12 Zymogenetics, Inc. Angiopoietin homolog zapo3, dna encoding it, and method of making it
ES2341926T3 (es) 1998-03-02 2010-06-29 Massachusetts Institute Of Technology Poliproteinas con dedos de cinc que tienen enlazadores mejorados.
WO1999045135A1 (en) * 1998-03-02 1999-09-10 Millennium Pharmaceuticals, Inc. Novel fdrg protein and nucleic acid molecules and uses therefor
US7488590B2 (en) * 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
EP2151454B1 (en) 1998-11-10 2012-05-02 Ludwig Institute For Cancer Research Truncated platelet-derived growth factor D, DNA coding therefor, and uses thereof
PL199645B1 (pl) 1998-12-23 2008-10-31 Regeneron Pharma Kwas nukleinowy, polipeptyd fuzyjny, kompozycja, wektor, wektor ekspresyjny, układ gospodarz wektor, sposób wytwarzania polipeptydu fuzyjnego, kwas nukleinowy i sposób wytwarzania polipeptydu fuzyjnego
AU3359600A (en) * 1999-03-02 2000-09-21 Regeneron Pharmaceuticals, Inc. Angiopoietin-related protein and nucleic acids
US6455035B1 (en) 1999-03-26 2002-09-24 Regeneron Pharmaceuticals, Inc. Angiopoietins and methods of use thereof
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
HK1045700B (zh) 1999-04-28 2007-07-27 德克萨斯大学董事会 用於通过选择性抑制vegf来治疗癌症的组合物和方法
US6521424B2 (en) 1999-06-07 2003-02-18 Immunex Corporation Recombinant expression of Tek antagonists
ATE324444T1 (de) 1999-06-07 2006-05-15 Immunex Corp Tek-antagonisten
EP1956030B1 (en) 1999-06-15 2009-11-11 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids endoding the same
US6689035B1 (en) 2000-04-11 2004-02-10 Gerber Scientific Products, Inc. Method and apparatus for designing and creating a package
CA2431308C (en) 2000-12-07 2010-04-13 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
AU2006228095B2 (en) * 2001-10-11 2010-11-04 Amgen Inc. Angiopoietin-2 specific binding agents
US7138370B2 (en) * 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7205275B2 (en) * 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU2002335085A1 (en) 2001-10-25 2003-05-06 Regeneron Pharmaceuticals, Inc. Angiopoietins and methods of use thereof
JP4242590B2 (ja) * 2002-01-11 2009-03-25 俊一 塩澤 慢性関節リウマチの疾患感受性遺伝子、及びその利用
US7427594B1 (en) * 2002-02-26 2008-09-23 The Trustees Of The University Of Pennsylvania Methods and pharmaceuticals compositions for treating coronary artery disease, ischemia,and vascular disease using angiopoietins
US7081443B2 (en) 2002-05-21 2006-07-25 Korea Advanced Institutes Of Science And Technology (Kaist) Chimeric comp-ang1 molecule
US20040115640A1 (en) * 2002-12-11 2004-06-17 Isis Pharmaceuticals Inc. Modulation of angiopoietin-2 expression
US7479270B2 (en) 2002-07-23 2009-01-20 Vegenics Limited Methods and compositions for activating VEGF-D and VEGF-C
WO2004045531A2 (en) 2002-11-14 2004-06-03 Cornell Research Foundation, Inc. Protection of cardiac myocardium
DK1648998T3 (en) 2003-07-18 2015-01-05 Amgen Inc Specific binding agents for hepatocyte growth factor
CN1323723C (zh) * 2003-12-26 2007-07-04 上海新世界基因技术开发有限公司 Tie2受体介导的靶向性肿瘤基因治疗的基因转移系统
US8298532B2 (en) * 2004-01-16 2012-10-30 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
US20060024302A1 (en) 2004-03-05 2006-02-02 Ludwig Institute For Cancer Research Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D antibodies and methods of using same
US8604185B2 (en) 2004-07-20 2013-12-10 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
ZA200701183B (en) * 2004-07-20 2008-05-28 Genentech Inc Inhibitors of angiopoietin-like 4 protein, combinations, an their use
CN105085678B (zh) 2004-12-21 2019-05-07 阿斯利康公司 血管生成素-2的抗体及其应用
MX2007008326A (es) * 2005-01-07 2008-01-16 Univ Emory Antagonistas de cxcr4 para el tratamiento de una infeccion por vih.
JP4657757B2 (ja) * 2005-02-23 2011-03-23 株式会社膠原病研究所 肺高血圧症発症関連遺伝子を用いた肺高血圧症の診断および治療
JP2006325528A (ja) * 2005-05-27 2006-12-07 Institute For Rheumatic Diseases Co Ltd 糖尿病性網膜症の診断および予防
JP4657857B2 (ja) * 2005-08-25 2011-03-23 株式会社膠原病研究所 メタボリックシンドロームの診断および予防
KR101371773B1 (ko) 2005-12-15 2014-03-07 아스트라제네카 아베 암 치료를 위한, 안지오포이에틴-2 길항자와 ｖｅｇｆ-ａ,ｋｄｒ 및/또는 ｆｌｔ1 길항자의 조합물
AR059066A1 (es) * 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
MX2008013990A (es) 2006-05-09 2009-01-29 Pfizer Prod Inc Derivados de cicloalquilamino acidos.
EP3330292A1 (en) 2007-08-21 2018-06-06 Amgen, Inc Human c-fms antigen binding proteins
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8227577B2 (en) * 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
AU2008346734A1 (en) 2008-01-03 2009-07-16 The Scripps Research Institute Antibody targeting through a modular recognition domain
RU2509085C2 (ru) 2008-01-28 2014-03-10 Медиммун Лимитед Стабилизированные антитела против ангиопоэтина-2 и их применение
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
EP2671891A3 (en) 2008-06-27 2014-03-05 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
US8133979B2 (en) 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
KR101431318B1 (ko) * 2009-04-02 2014-08-20 로슈 글리카트 아게 전장 항체 및 단일쇄 ｆａｂ 단편을 포함하는 다중특이성 항체
JP5616428B2 (ja) 2009-04-07 2014-10-29 ロシュ グリクアート アクチェンゲゼルシャフト 三価の二重特異性抗体
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US8980268B2 (en) 2009-07-29 2015-03-17 Regeneron Pharamceuticals, Inc. Methods for treating cancer by administering an anti-Ang-2 antibody
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
US20120189635A1 (en) 2009-07-29 2012-07-26 Regeneron Pharmaceuticals, Inc. Methods for Treating or Preventing Malaria by Administering an Antibody that Specifically Binds Angiopoietin-2 (Ang-2)
CA2781519A1 (en) 2009-09-16 2011-03-24 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
WO2011038139A1 (en) 2009-09-23 2011-03-31 Amgen Inc. Treatment of ovarian cancer using a specific binding agent of human angiopoietin-2 in combination with a taxane
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
EP2609111B1 (en) 2010-08-24 2017-11-01 F. Hoffmann-La Roche AG Bispecific antibodies comprising a disulfide stabilized-fv fragment
JP5766296B2 (ja) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
WO2012116927A1 (en) 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Monovalent antigen binding proteins
MX341921B (es) 2011-02-28 2016-09-07 Hoffmann La Roche Proteinas de union a antigeno.
EP2714738B1 (en) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
WO2013003606A1 (en) 2011-06-29 2013-01-03 Amgen Inc. Predictive biomarker of survival in the treatment of renal cell carcinoma
KR102063028B1 (ko) 2012-01-23 2020-01-07 리제너론 파아마슈티컬스, 인크. 항-ａｎｇ2 항체를 함유하는 안정화된 제형
EP2812357B1 (en) 2012-02-10 2020-11-04 F.Hoffmann-La Roche Ag Single-chain antibodies and other heteromultimers
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
US20150044227A1 (en) 2012-03-08 2015-02-12 Medimmune, Llc Methods of treatment with angiopoietin-2 antibodies
JP5970734B2 (ja) 2012-03-30 2016-08-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ａｎｇ２結合分子
KR20150030744A (ko) 2012-06-27 2015-03-20 에프. 호프만-라 로슈 아게 표적에 특이적으로 결합하는 하나 이상의 결합 단위를 포함하는 항체 Ｆｃ－영역 접합체의 제조 방법 및 그의 용도
RU2639287C2 (ru) 2012-06-27 2017-12-20 Ф. Хоффманн-Ля Рош Аг Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
SMT202100621T1 (it) 2012-07-13 2022-01-10 Roche Glycart Ag Anticorpi bispecifici anti-vegf/anti-ang-2 e loro impiego nel trattamento delle malattie vascolari oculari
WO2014108854A1 (en) 2013-01-09 2014-07-17 Fusimab Ltd. Monospecific anti-hgf and anti-ang2 antibodies and bispecific anti-hgf/anti-ang2 antibodies
CA2907181C (en) 2013-03-15 2023-10-17 Viktor Roschke Multivalent and monovalent multispecific complexes and their uses
KR20160044060A (ko) 2013-10-11 2016-04-22 에프. 호프만-라 로슈 아게 다중특이적 도메인 교환된 통상의 가변 경쇄 항체
AU2014407088B2 (en) 2014-09-26 2021-09-23 Somalogic Operating Co., Inc. Cardiovascular risk event prediction and uses thereof
WO2016061551A1 (en) 2014-10-17 2016-04-21 Amgen Inc. Antibodies directed to angiopoietin-1 and angiopoietin-2 for ocular therapies
JP6721590B2 (ja) 2014-12-03 2020-07-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 多重特異性抗体
BR112017018885A2 (pt) 2015-03-04 2018-04-17 Mesoblast Int Sarl método de cultura celular para células-tronco mesenquimais
US20190004048A1 (en) 2015-06-26 2019-01-03 Amgen Inc. Biomarker of Survival in the Treatment of Renal Cell Carcinoma with a VEGFR Inhibitor and an Ang2 Inhibitor
EA202192290A1 (ru) 2015-12-16 2022-02-28 Ридженерон Фармасьютикалз, Инк. Композиции и способы получения белковых микрочастиц
US10836819B2 (en) 2016-08-23 2020-11-17 Medimmune Limited Anti-VEGF-A and anti-ANG2 antibodies and uses thereof
WO2018140887A1 (en) 2017-01-30 2018-08-02 Regeneron Pharmaceuticals, Inc. Method for reducing bioburden in chromatography
AU2018347521A1 (en) 2017-10-12 2020-05-07 Immunowake Inc. VEGFR-antibody light chain fusion protein
MX2021004774A (es) 2018-10-29 2021-08-24 Hoffmann La Roche Formulacion de anticuerpos.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
AU8143094A (en) * 1993-11-12 1995-05-29 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. (tie-2), a novel receptor tyrosine kinase
US5879672A (en) * 1994-10-07 1999-03-09 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 1
CA2331789C (en) * 1998-07-13 2013-09-10 Board Of Regents, The University Of Texas System Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids

Also Published As

Publication number Publication date
DK0784683T3 (da) 2001-03-19
AU711111B2 (en) 1999-10-07
NO971557L (no) 1997-06-06
EP0784683B1 (en) 2001-02-21
IL115517A0 (en) 1996-01-19
CA2202028C (en) 2011-12-20
ATE199259T1 (de) 2001-03-15
DE69520149T2 (de) 2001-08-30
IL115517A (en) 2004-12-15
FI971406A7 (fi) 1997-06-04
US6645484B1 (en) 2003-11-11
PT784683E (pt) 2001-07-31
IL154113A0 (en) 2003-07-31
AU4129596A (en) 1996-05-02
US6166185A (en) 2000-12-26
JPH10509583A (ja) 1998-09-22
CN1230536C (zh) 2005-12-07
US5814464A (en) 1998-09-29
EP0784683A1 (en) 1997-07-23
WO1996011269A2 (en) 1996-04-18
IL140138A0 (en) 2002-02-10
HUT77491A (hu) 1998-05-28
IL140137A0 (en) 2002-02-10
CA2202028A1 (en) 1996-04-18
ZA958444B (en) 2014-06-25
DE69520149D1 (de) 2001-03-29
CZ102597A3 (en) 1997-09-17
IL140138A (en) 2005-03-20
ES2154354T3 (es) 2001-04-01
NO971557D0 (no) 1997-04-04
FI120313B (fi) 2009-09-15
IL140137A (en) 2005-03-20
CZ292453B6 (cs) 2003-09-17
US6433143B1 (en) 2002-08-13
PL184642B1 (pl) 2002-11-29
NO322643B1 (no) 2006-11-13
HK1005944A1 (en) 1999-02-05
JP4054375B2 (ja) 2008-02-27
PL319586A1 (en) 1997-08-18
HU221422B1 (en) 2002-09-28
GR3035717T3 (en) 2001-07-31
NZ296638A (en) 1999-03-29
CN1167505A (zh) 1997-12-10
MX9702530A (es) 1998-02-28

Similar Documents

Publication Publication Date Title
FI971406A0 (fi) TIE-2-ligandeja ja menetelmiä niiden valmistamiseksi ja käyttämiseksi
EP0821728A4 (en) TIE-2 LIGANDS, METHODS OF OBTAINING SUCH LIGANDS, AND USES THEREOF
Kadin et al. Eosinophils are the major source of transforming growth factor-beta 1 in nodular sclerosing Hodgkin's disease
FI982745A0 (fi) TIE-2-reseptoriligandit (TIE-ligandi-3; TIE-ligandi-4) ja niiden käyttö
US20100040618A1 (en) Prevention of tumors with monoclonal antibodies against neu
WO1994022478A1 (en) PREVENTION OF TUMORS WITH MONOCLONAL ANTIBODIES AGAINST $i(NEU)
RU94045281A (ru) Иммуноконъюгаты, способ получения иммуноконъюгата, фармацевтическая композиция, применение иммуноконъюгата
LU91117I2 (en) Cetuximab in combination with irinotecan.
DE3268915D1 (en) Angiotropins of leukocytes and inflamed tissue: a new class of natural chemotropic protein mitogens for specific induction of directional growth of blood vessels, neovascularization of tissues and morphogenesis of blood vessel patterns, process for their biotechnical preparation and pharmaceutical compositions
DE69034112D1 (de) Antikörper gegen Lymphozyten-assoziiertes Zelloberflächenprotein
AU2001235761A1 (en) Diagnosis of breast cancer using bcmp-11 as marker
DE50015355D1 (de) Mit trp-proteinen verwandtes protein mtr1 und dieses codierende dna-sequenz

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 120313

Country of ref document: FI

MA Patent expired